These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 8077474)
1. Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene. Stricker RB; Elswood BF; Goldberg B; Dumlao C; Van Elk J; Henry J; Winger EE; Epstein WL J Am Acad Dermatol; 1994 Sep; 31(3 Pt 1):462-6. PubMed ID: 8077474 [TBL] [Abstract][Full Text] [Related]
2. Topical immune modulation with dinitrochlorobenzene in HIV disease: a controlled trial from Brazil. Traub A; Margulis SB; Stricker RB Dermatology; 1997; 195(4):369-73. PubMed ID: 9529559 [TBL] [Abstract][Full Text] [Related]
3. Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene. Stricker RB; Goldberg B; Mills LB; Epstein WL J Am Acad Dermatol; 1995 Oct; 33(4):608-11. PubMed ID: 7673493 [TBL] [Abstract][Full Text] [Related]
4. Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection. Stricker RB; Zhu YS; Elswood BF; Dumlao C; Van Elk J; Berger TG; Tappero J; Epstein WL; Kiprov DD Immunol Lett; 1993 Apr; 36(1):1-6. PubMed ID: 8102123 [TBL] [Abstract][Full Text] [Related]
5. Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease. Stricker RB; Goldberg B; Mills LB; Epstein WL Res Virol; 1997; 148(5):343-8. PubMed ID: 9403933 [TBL] [Abstract][Full Text] [Related]
6. [T-lymphocyte immune in HIV-infected people and AIDS patients in China]. Li T; Qiu Z; Wang A; Sheng R Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1391-5. PubMed ID: 12509921 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Stricker RB; Elswood BF Immunol Lett; 1991 Aug; 29(3):191-6. PubMed ID: 1769706 [TBL] [Abstract][Full Text] [Related]
8. Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non--rapid progressor children. Paul ME; Shearer WT; Kozinetz CA; Lewis DE J Allergy Clin Immunol; 2001 Aug; 108(2):258-64. PubMed ID: 11496243 [TBL] [Abstract][Full Text] [Related]
9. Determination of T-lymphocyte subsets on site in rural Tanzania: results in HIV-1 infected and non-infected individuals. Levin A; Brubaker G; Shao JS; Kumby D; O'Brien TR; Goedert JJ; Strauss KW; Blattner WA; Hannet I Int J STD AIDS; 1996 Jul; 7(4):288-91. PubMed ID: 8876362 [TBL] [Abstract][Full Text] [Related]
10. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945 [TBL] [Abstract][Full Text] [Related]
11. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children. Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091 [TBL] [Abstract][Full Text] [Related]
12. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART. Choremi-Papadopoulou H; Tsalimalma K; Dafni U; Dimitracopoulou A; Kordossis T J Med Virol; 2004 Jun; 73(2):235-43. PubMed ID: 15122798 [TBL] [Abstract][Full Text] [Related]
13. [Characteristics of immunophenotypic alterations in 263 HIV/AIDS patients]. Xie J; Qiu ZF; Li TS; Han Y; Zuo LY; Ma XJ; Liu ZY; Wang AX Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):965-9. PubMed ID: 16759536 [TBL] [Abstract][Full Text] [Related]
14. Topical immune modulation (TIM): a novel approach to the immunotherapy of systemic disease. Stricker RB; Goldberg B; Epstein WL Immunol Lett; 1997 Dec; 59(3):145-50. PubMed ID: 9419021 [TBL] [Abstract][Full Text] [Related]
15. [The correlation between HLA-DR or CD38 expression in CD8(+)T cells and CD4(+)T cells count in treatment-naive HIV/AIDS patients]. Xie J; Qiu Z; Han Y; Li Y; Song X; Li T Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):36-9. PubMed ID: 26796651 [TBL] [Abstract][Full Text] [Related]
16. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy. d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625 [TBL] [Abstract][Full Text] [Related]
17. Different meaning of CD38 molecule expression on CD4+ and CD8+ cells of children perinatally infected with human immunodeficiency virus type 1 infection surviving longer than five years. de Martino M; Rossi ME; Azzari C; Gelli MG; Galli L; Vierucci A Pediatr Res; 1998 Jun; 43(6):752-8. PubMed ID: 9621984 [TBL] [Abstract][Full Text] [Related]